Sorry, you need to enable JavaScript to visit this website.
Skip to main content

All materials and content available on the website are of strictly non-promotional nature and only intended for healthcare professionals (HCPs) practicing in Europe. Kindly note that materials and content are not intended for any specific country and approval conditions for products may vary from country to country. Before prescribing any product, always refer to the approved label in the relevant country and/or the Summary of Product Characteristics.

  • September 05, 2022
  • Iron Deficiency

Global Heart Failure Academy

Explore the science
  • July 07, 2022
  • ANCA-associated vasculitis

The science of complement antagonism in ANCA vasculitis – current understanding

Explore the science
  • June 30, 2022
  • ANCA-associated vasculitis

Avacopan as first-line treatment in antineutrophil cytoplasmic antibody-associated vasculitis: A steroid-sparing option

Explore the science
  • June 30, 2022
  • ANCA-associated vasculitis

Compassionate use of Avacopan in difficult-to-treat ANCA-associated vasculitis

Explore the science
  • June 30, 2022
  • ANCA-associated vasculitis

ANCA 2022 Symposia: Transforming outcomes in AAV by targeting C5aR-mediated inflammation

Explore the science
  • June 30, 2022
  • ANCA-associated vasculitis

Exploring the unmet needs of people suffering with ANCA-associated vasculitis (AAV)

Explore the science
  • June 30, 2022
  • ANCA-associated vasculitis

AAV Disease awareness MoD video

Explore the science
  • June 08, 2022
  • Hyperkalemia

Optimization of RAASi and low risk of hyperkalemia with potassium binder in HFrEF

Explore the science
  • February 18, 2022
  • CKD-MBD and SHPT

Establishing 25(OH)D-level adequacy in patients with ND-CKD

Explore the science